ARKG is trading 3.2% up today as healthcare and biotech stocks rally alongside broader market gains in the S&P 500 and Nasdaq.
- Easing Middle East tensions, lower oil prices, and supportive Treasury moves are improving risk appetite for growth and innovation-oriented sectors like genomics.
- Positive regulatory news, including Novartis’s expanded FDA approval for Pluvicto, is reinforcing the outlook for specialized therapies and boosting sentiment across the healthcare sector.